Targeting DYRK1a to improve heart recovery after a heart attack
DYRK1a as a therapeutic target to treat myocardial infarction
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-10885024
This study is looking at how a special protein called DYRK1a might help heart muscle cells recover after a heart attack, with the hope of finding new treatments that can improve heart function and prevent problems like heart failure for people who have had a heart attack.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-10885024 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting a specific protein, DYRK1a, can help protect heart muscle cells after a heart attack. The study aims to identify drugs that can stimulate the regeneration of these cells, which are often lost even after successful treatment of the heart attack. By using advanced mouse models, researchers will explore how manipulating DYRK1a can enhance heart function and reduce complications like heart failure and arrhythmias. The ultimate goal is to develop new therapies that can effectively replace lost heart muscle and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have experienced a myocardial infarction and are seeking new treatment options to improve their heart function.
Not a fit: Patients who have not had a heart attack or those with advanced heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help the heart recover better after a heart attack, potentially reducing the risk of heart failure and improving overall heart health.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for heart recovery, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOLF, MATTHEW J — UNIVERSITY OF VIRGINIA
- Study coordinator: WOLF, MATTHEW J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.